The launch of Index Ventures’ new life sciences fund on March 21st is another big step in the reincarnation of the biotech investment model. As a smaller, focused fund it will carry even further the “asset-centric” strategy Index have championed. But the most obvious new feature is the inclusion of two global pharmaceutical giants as strategic investors in the fund.
It is, therefore, a very different beast from most venture capital funds, particularly in the US. Different doesn’t always mean better, so DrugBaron asks what would be the optimal parameters for a life sciences fund to have in 2012, and measures this new entrant against that yardstick
RxCelerate Ltd is an outsourced drug development platform based near Cambridge, UK. We specialize in delivering an entire road map of drug development services from discovery and medicinal chemistry through to formal preclinical development and clinical up to Phase IIa.
In the last five years, we have witnessed dramatic changes in the drug development landscape, with the proliferation of virtua